OrbiMed, Wellington backers of Chinese biotech Gracell

Sergio BarretoOctober 29, 2020

1 minute read

OrbiMed, Wellington backers of Chinese biotech Gracell — Shanghai cityscape by Dibrova

Wellington Management Company and Morningside Ventures joined healthcare investment specialists OrbiMed and Vivo Capital to lead a $100 million Series C round for Gracell Biotechnologies.

"We are . . .

Continue Reading With a Free Trial

Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.

Already a subscriber? Log in.

Sergio Barreto

Sergio Barreto is about 70% journalist, 30% tech geek. As an editor for The ABIS Group, he produces daily newsletters for leading healthcare and technology companies. With BMV Digital, he provides WordPress-based web developments services. Here at Alternatives Watch, he wears both hats - handling IT and occasionally writing about the intersection of alts, healthcare and tech.